Korea Passing: Real-Life Examples of the Term in Use
What Is Korea Passing and Where It's Used
Korea Passing refers to two main scenarios: In finance and business, it describes situations where foreign companies or policies exclude South Korea; in the pharmaceutical industry, it refers to global drugmakers delaying the introduction of innovative new drugs.
Finance and Business Examples
A notable case involves SpaceX's initial public offering (IPO) process, where Korean institutions were reportedly excluded. According to a June 14, 2026 report, SpaceX informed Mirae Asset that it would assign zero shares, while Goldman Sachs also notified Mirae Asset just 90 minutes before market open that they received 'zero shares.' This led to the term Korea Passing being used.
Related reports suggested Korean institutions were excluded from a $3 trillion event without invitations. However, these reports did not confirm specific allocation details or quantities.
Pharmaceutical Industry Examples
In the pharmaceutical sector, Korea Passing occurs when innovative new drugs are not included in government reimbursement programs, as global drugmakers delay introducing them. Discussions around this issue have intensified since 2025, with proposals such as flexible application of the 'dual pricing system' and introduction of a 'price flexibility agreement' being suggested as solutions.
A March 10, 2026 report noted that pharmaceutical companies are avoiding new drug reimbursement due to concerns over high costs—up to tens of thousands of won. This is considered a direct example of Korea Passing, highlighting the urgency for policy improvements.
Clarifying Trump's Misunderstood Statement
Former President Trump never used the term 'Korea Passing.' Instead, he stated, 'There will be no bypassing of South Korea,' according to a November 7, 2017 report. Subsequent media coverage incorrectly expanded this into the term 'Korea Passing.'
This misunderstanding spread in reports related to the Moon Jae-in administration but has been clarified as unrelated to Trump's actual remarks. Thus, the term 'Korea Passing' was mistakenly derived from a misinterpretation of his statement.

Unification Ministry Report and North Korea-U.S. Dialogue Boundaries
A 2026 September 13 report by the Unification Ministry's consulting study warned about 'Korea Passing,' cautioning that hasty North Korea-U.S. dialogue could mistakenly lead to recognition of North Korean nuclear weapons. The report highlighted risks of South Korea being overlooked in such discussions.
The Unification Ministry report used the term 'Korea Passing' to express concern over potential diplomatic isolation, emphasizing the risk of South Korea's role being sidelined during North Korea-U.S. negotiations.
Potential Policy Solutions
To address Korea Passing issues, government and pharmaceutical companies are discussing several solutions. Flexible application of the dual pricing system is needed, along with successful implementation conditions for price flexibility agreements.
A January 8, 2025 report suggested that addressing 'Korea Passing' requires flexible use of the dual pricing system. A April 28, 2026 report titled 'Solving Korea Passing... Implementation of Price Flexibility Agreement' highlighted policy measures aimed at resolving this issue.
Root Causes of Korea Passing
The primary cause of Korea Passing relates to pharmaceutical pricing policies, particularly the scope and method of applying the 'dual pricing system' and 'price flexibility agreement.' A October 12, 2025 report analyzed why global drugmakers delay introducing new drugs, emphasizing the need for more flexible pricing calculations.
The medical community and pharmacy associations have also highlighted Korea Passing concerns, advocating for greater pricing flexibility. A November 28, 2025 report proposed increasing drug prices and expanding dual pricing to prevent delays in new drug adoption.
Responses and Safety Information
The government is exploring various measures to resolve Korea Passing issues. A March 18, 2026 report discussed successful implementation conditions for the immediate introduction of price flexibility agreements, signaling enhanced cooperation between pharmaceutical companies and the government.
Additonally, a March 17, 2025 report noted the need for flexible adjustments to essential drug reimbursement rates under national health insurance. These policies aim to increase pricing flexibility and alleviate Korea Passing concerns.
Key Information to Verify
Some reports on Korea Passing mistakenly interpreted Trump's statement; he never said 'Korea Passing' but rather stated, 'There will be no bypassing of South Korea.' Additionally, the Unification Ministry report's mention of 'Korea Passing' refers to concerns about North Korea-U.S. dialogue potentially sidelining South Korea's diplomatic position.
In finance and business, the SpaceX and Goldman Sachs share allocation case is a notable example, though specific allocation details remain unconfirmed. In pharmaceuticals, Korea Passing persists due to new drug reimbursement issues, necessitating policy improvements.
Frequently Asked Questions
What does Korea Passing refer to?
Korea Passing describes situations where South Korea is excluded in finance/business contexts or where innovative drugs are delayed in the pharmaceutical industry.
Did President Trump say 'Korea Passing'?
No, Trump stated, 'There will be no bypassing of South Korea,' and the term was misinterpreted from this statement.
What policies address Korea Passing?
The flexible application of the dual pricing system and introduction of price flexibility agreements are key solutions proposed to resolve Korea Passing.
Frequently Asked Questions
Korea Passing is a term used in both finance/business and pharmaceutical sectors, requiring accurate understanding within each context. Clarifying misunderstandings like Trump's statement and linking the Unification Ministry report's caution with North Korea-U.S. dialogue boundaries helps present policy solutions clearly. This approach supports South Korea's ability to respond to external pressures and foster industry growth through coordinated government-private sector efforts.
Comprehensively addressing Korea Passing across political, economic, and healthcare sectors is essential for strengthening South Korea's competitiveness. To achieve this, collaboration between government and private entities must develop and implement flexible policies.
Explore more articles on similar topics in one place.
View Related ArticlesFAQ
What does Korea Passing refer to?
Korea Passing describes situations where South Korea is excluded in finance/business contexts or where innovative drugs are delayed in the pharmaceutical industry.
Did President Trump say 'Korea Passing'?
No, Trump stated, 'There will be no bypassing of South Korea,' and the term was misinterpreted from this statement.
What policies address Korea Passing?
The flexible application of the dual pricing system and introduction of price flexibility agreements are key solutions proposed to resolve Korea Passing.
Korean Source
This article is an English localization of a Korean-language report from BlogScore. Original: 코리아 패싱 한국어 사용법 실제 예시 5가지